Difference between revisions of "Vortioxetine-moclobemide"

From Psychiatrienet
Jump to: navigation, search
Line 4: Line 4:
 
| stop =  
 
| stop =  
 
* '''Day 1:''' reduce dosage of vortioxetine to 5 mg/day.
 
* '''Day 1:''' reduce dosage of vortioxetine to 5 mg/day.
* '''Day 7:''' stop administration of vortioxetine.
+
* '''Day 8:''' stop administration of vortioxetine.
 
| start =  
 
| start =  
 
* '''Day 8-22:''' a wash-out period of 2 weeks is necessary.
 
* '''Day 8-22:''' a wash-out period of 2 weeks is necessary.

Revision as of 13:04, 12 March 2015

Vortioxetine
Type Antidepressant
Group SMS
links
Medscape Vortioxetine
PubChem 9966051
PubMed Vortioxetine
Kompas (Dutch) Vortioxetine
Wikipedia Vortioxetine
Moclobemide
Type Antidepressant
Group MAO-I
links
Medscape Moclobemide
PubChem 4235
PubMed Moclobemide
Kompas (Dutch) Moclobemide
Wikipedia Moclobemide

Switch medication from vortioxetine to moclobemide.[1] [2]

Nietinrijdenbord.png Stop vortioxetine
  • Day 1: reduce dosage of vortioxetine to 5 mg/day.
  • Day 8: stop administration of vortioxetine.
Eenrichtingbord.png Start moclobemide
  • Day 8-22: a wash-out period of 2 weeks is necessary.
  • Day 23: start administration of moclobemide in normal dosage of 300 mg/day.
Letopbord.png Cave


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.